Showing results (331-340 of 458) with videos related to
Sort By:
Pageof 46
Pediatric Blood & Cancer|April 20, 2016
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca, Samuel L Volchenboum, Hwangeui Cho, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 17, 2025
The Non-Coding Regulatory Variant rs2863002 at chr11p11.2 Increases Neuroblastoma Risk by Affecting HSD17B12 Expression and Lipid MetabolismTeresa Maiorino, Marianna Avitabile, Vincenzo Aievola, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2016
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaLori S Hart, JulieAnn Rader, Pichai Raman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2021
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology GroupMeredith S Irwin, Arlene Naranjo, Fan F Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signatureKatleen De Preter, Joëlle Vermeulen, Benedikt Brors, et al.Molecular Cancer Therapeutics|May 11, 2019
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsMehran Makvandi, Hwan Lee, Laura N Puentes, et al.Journal of the National Cancer Institute|January 31, 2019
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune EvasionSabine Heitzeneder, Elena Sotillo, Jack F Shern, et al.Cancer Research|June 24, 2015
CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility LocusMike R Russell, Annalise Penikis, Derek A Oldridge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) TrialSteven G DuBois, Araz Marachelian, Elizabeth Fox, et al.Cancer Research|November 25, 2003
Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2Jieyi Wang, George S Sheppard, Pingping Lou, et al.Pageof 46